Dopamine- and CAMP-regulated Phosphoprotein of 32-kDa (DARPP-32)-dependent Activation of Extracellular Signal-regulated Kinase (ERK) and Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling in Experimental Parkinsonism

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2012 Jul 4

PMID 22753408

Citations 40

Authors

Emanuela Santini

Michael Feyder

Giuseppe Gangarossa

Helen S Bateup

Paul Greengard

Gilberto Fisone

Affiliations

Soon will be listed here.

Abstract

Dyskinesia, a motor complication caused by prolonged administration of the antiparkinsonian drug l-3,4-dihydroxyphenylalanine (l-DOPA), is accompanied by activation of cAMP signaling and hyperphosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32). Here, we show that the abnormal phosphorylation of DARPP-32 occurs specifically in medium spiny neurons (MSNs) expressing dopamine D1 receptors (D1R). Using mice in which DARPP-32 is selectively deleted in D1R-expressing MSNs, we demonstrate that this protein is required for l-DOPA-induced activation of the extracellular signal-regulated protein kinases 1 and 2 and the mammalian target of rapamycin complex 1 (mTORC1) pathways, which are implicated in dyskinesia. We also show that mutation of the phosphorylation site for cAMP-dependent protein kinase on DARPP-32 attenuates l-DOPA-induced dyskinesia and reduces the concomitant activations of ERK and mTORC1 signaling. These studies demonstrate that, in D1R-expressing MSNs, l-DOPA-induced activation of ERK and mTORC1 requires DARPP-32 and indicates the importance of the cAMP/DARPP-32 signaling cascade in dyskinesia.

Citing Articles

Differential Activation States of Direct Pathway Striatal Output Neurons during l-DOPA-Induced Dyskinesia Development.

Figge D, Amaral H, Crim J, Cowell R, Standaert D, Eskow Jaunarajs K J Neurosci. 2024; 44(26).

PMID: 38664012 PMC: 11211726. DOI: 10.1523/JNEUROSCI.0050-24.2024.

Detrimental effects of soluble α-synuclein oligomers at excitatory glutamatergic synapses.

Ferrari E, Salvade M, Zianni E, Brumana M, DiLuca M, Gardoni F Front Aging Neurosci. 2023; 15:1152065.

PMID: 37009450 PMC: 10060538. DOI: 10.3389/fnagi.2023.1152065.

Striatal Subregion-selective Dysregulated Dopamine Receptor-mediated Intracellular Signaling in a Model of DOPA-responsive Dystonia.

Roman K, Briscione M, Donsante Y, Ingram J, Fan X, Bernhard D Neuroscience. 2023; 517:37-49.

PMID: 36871883 PMC: 10085842. DOI: 10.1016/j.neuroscience.2023.02.020.

D2R signaling in striatal spiny neurons modulates L-DOPA induced dyskinesia.

Florio E, Serra M, Lewis R, Kramar E, Freidberg M, Wood M iScience. 2022; 25(10):105263.

PMID: 36274959 PMC: 9579025. DOI: 10.1016/j.isci.2022.105263.

Dopamine D receptor-mediated β-arrestin signaling: Insight from pharmacology, biology, behavior, and neurophysiology.

Yang Y, Lewis M, Huang X, Dokholyan N, Mailman R Int J Biochem Cell Biol. 2022; 148:106235.

PMID: 35688404 PMC: 10266066. DOI: 10.1016/j.biocel.2022.106235.

References

Santini E, Sgambato-Faure V, Li Q, Savasta M, Dovero S, Fisone G . Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia. PLoS One. 2010; 5(8):e12322. PMC: 2925943. DOI: 10.1371/journal.pone.0012322. View

Darmopil S, Martin A, De Diego I, Ares S, Moratalla R . Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Biol Psychiatry. 2009; 66(6):603-13. DOI: 10.1016/j.biopsych.2009.04.025. View

Costa-Mattioli M, Sossin W, Klann E, Sonenberg N . Translational control of long-lasting synaptic plasticity and memory. Neuron. 2009; 61(1):10-26. PMC: 5154738. DOI: 10.1016/j.neuron.2008.10.055. View

Westin J, Vercammen L, Strome E, Konradi C, Cenci M . Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiatry. 2007; 62(7):800-10. PMC: 4205578. DOI: 10.1016/j.biopsych.2006.11.032. View

Bateup H, Santini E, Shen W, Birnbaum S, Valjent E, Surmeier D . Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. Proc Natl Acad Sci U S A. 2010; 107(33):14845-50. PMC: 2930415. DOI: 10.1073/pnas.1009874107. View

Ruvinsky I, Meyuhas O . Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci. 2006; 31(6):342-8. DOI: 10.1016/j.tibs.2006.04.003. View

Marshall J, Ungerstedt U . Supersensitivity to apomorphine following destruction of the ascending dopamine neurons: quantification using the rotational model. Eur J Pharmacol. 1977; 41(4):361-7. DOI: 10.1016/0014-2999(77)90256-4. View

Lebel M, Chagniel L, Bureau G, Cyr M . Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat. Neurobiol Dis. 2010; 38(1):59-67. DOI: 10.1016/j.nbd.2009.12.027. View

Roux P, Ballif B, Anjum R, Gygi S, Blenis J . Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci U S A. 2004; 101(37):13489-94. PMC: 518784. DOI: 10.1073/pnas.0405659101. View

10.

Towbin H, Staehelin T, Gordon J . Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979; 76(9):4350-4. PMC: 411572. DOI: 10.1073/pnas.76.9.4350. View

11.

Valjent E, Pascoli V, Svenningsson P, Paul S, Enslen H, Corvol J . Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc Natl Acad Sci U S A. 2004; 102(2):491-6. PMC: 544317. DOI: 10.1073/pnas.0408305102. View

12.

Santini E, Alcacer C, Cacciatore S, Heiman M, Herve D, Greengard P . L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. J Neurochem. 2009; 108(3):621-33. DOI: 10.1111/j.1471-4159.2008.05831.x. View

13.

Gerfen C, Engber T, Mahan L, Susel Z, Chase T, Monsma Jr F . D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 1990; 250(4986):1429-32. DOI: 10.1126/science.2147780. View

14.

Hemmings Jr H, Greengard P, Tung H, Cohen P . DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature. 1984; 310(5977):503-5. DOI: 10.1038/310503a0. View

15.

Santini E, Heiman M, Greengard P, Valjent E, Fisone G . Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia. Sci Signal. 2009; 2(80):ra36. DOI: 10.1126/scisignal.2000308. View

16.

Schuster S, Nadjar A, Guo J, Li Q, Ittrich C, Hengerer B . The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease. J Neurosci. 2008; 28(17):4311-6. PMC: 6670943. DOI: 10.1523/JNEUROSCI.4720-07.2008. View

17.

Svenningsson P, Tzavara E, Carruthers R, Rachleff I, Wattler S, Nehls M . Diverse psychotomimetics act through a common signaling pathway. Science. 2003; 302(5649):1412-5. DOI: 10.1126/science.1089681. View

18.

Thomas G, Huganir R . MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci. 2004; 5(3):173-83. DOI: 10.1038/nrn1346. View

19.

Santini E, Valjent E, Usiello A, Carta M, Borgkvist A, Girault J . Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci. 2007; 27(26):6995-7005. PMC: 6672217. DOI: 10.1523/JNEUROSCI.0852-07.2007. View

20.

Greengard P . The neurobiology of slow synaptic transmission. Science. 2001; 294(5544):1024-30. DOI: 10.1126/science.294.5544.1024. View